Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C; all Archway Investigators.
Holekamp NM, et al.
Ophthalmology. 2022 Mar;129(3):295-307. doi: 10.1016/j.ophtha.2021.09.016. Epub 2021 Sep 29.
Ophthalmology. 2022.
PMID: 34597713
Free article.
Clinical Trial.